Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management

The Lancet Neurology

Volumn 17, Issue 3, 2018, Pages 251-267

  Birnkrant, David J ^a   Bushby, Katharine ^b   Bann, Carla M ^c   Apkon, Susan D ^d   Blackwell, Angela ^c   Brumbaugh, David ^e   Case, Laura E ^f   Clemens, Paula R ^g   Hadjiyannakis, Stasia ^h   Pandya, Shree ⁱ   Street, Natalie ^j   Tomezsko, Jean ^k   Wagner, Kathryn R ^l   Ward, Leanne M ^h   Weber, David R ^m  

^a METROHEALTH MEDICAL CENTER   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c RTI INTERNATIONAL   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e CHILDREN S HOSPITAL COLORADO   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^j NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^k CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN;

ADRENAL INSUFFICIENCY; CLINICAL ASSESSMENT; DIET THERAPY; DUCHENNE MUSCULAR DYSTROPHY; DYSPHAGIA; EMERGENCY CARE; GROWTH; HUMAN; NEWBORN SCREENING; NONHUMAN; NUTRITIONAL ASSESSMENT; PHYSIOTHERAPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PUBERTY; REVIEW; SPEECH AND LANGUAGE REHABILITATION; DISEASE MANAGEMENT; ENDOCRINE SYSTEM; GASTROINTESTINAL TRACT; NEUROMUSCULAR JUNCTION; PATHOLOGY; PATHOPHYSIOLOGY;

DISEASE MANAGEMENT; ENDOCRINE SYSTEM; GASTROINTESTINAL TRACT; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; NEUROMUSCULAR JUNCTION; NUTRITION THERAPY;

EID: 85040788785     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(18)30024-3     Document Type: Review

References (129)

1. Ryder, S, Leadley, RM, Armstrong, N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis, 12, 2017, 79.
2. Mendell, JR, Shilling, C, Leslie, ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71 (2012), 304–313.
3. Moat, SJ, Bradley, DM, Salmon, R, Clarke, A, Hartley, L, Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet 21 (2013), 1049–1053.
4. Guiraud, S, Chen, H, Burns, DT, Davies, KE, Advances in genetic therapeutic strategies for Duchenne muscular dystrophy. Exp Physiol 100 (2015), 1458–1467.
5. Van Ruiten, H, Bushby, K, Guglieri, M, State of the art advances in Duchenne muscular dystrophy. EMJ 2 (2017), 90–99.
6. Bushby, K, Finkel, R, Birnkrant, DJ, et al., for the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9 (2010), 77–93.
7. Bushby, K, Finkel, R, Birnkrant, DJ, et al., for the DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9 (2010), 177–189.
8. TREAT-NMD. Family guide in different languages. http://www.treat-nmd.eu/dmd/care/family-guide/translations/, 2016 (accessed March 8, 2016).
9. McNally, EM, Kaltman, JR, Benson, DW, et al. the Working Group of the National Heart, Lung, and Blood Institute, Parent Project Muscular Dystrophy. Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation 131 (2015), 1590–1598.
10. Birnkrant, DJ, Bushby, KM, Amin, RS, et al. The respiratory management of patients with Duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 45 (2010), 739–748.
11. Passamano, L, Taglia, A, Palladino, A, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol 31 (2012), 121–125.
12. Saito, T, Kawai, M, Kimura, E, et al. Study of Duchenne muscular dystrophy long-term survivors aged 40 years and older living in specialized institutions in Japan. Neuromuscul Disord 27 (2017), 107–114.
13. Shimizu-Motohashi, Y, Miyatake, S, Komaki, H, Takeda, S, Aoki, Y, Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. Am J Transl Res 8 (2016), 2471–2489.
14. Griggs, RC, Miller, JP, Greenberg, CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology 87 (2016), 2123–2131.
15. Guglieri, M, Bushby, K, McDermott, MP, et al. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemp Clin Trials 58 (2017), 34–39.
16. Gloss, D, Moxley, RT 3rd, Ashwal, S, Oskoui, M, Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86 (2016), 465–472.
17. Fitch, K, Bernstein, SJ, Aguilar, MD, et al. The RAND/UCLA Appropriateness Method user's manual. 2001, RAND, Santa Monica, CA.
18. Ciafaloni, E, Fox, DJ, Pandya, S, et al. Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr 155 (2009), 380–385.
19. Mirski, KT, Crawford, TO, Motor and cognitive delay in Duchenne muscular dystrophy: implication for early diagnosis. J Pediatr 165 (2014), 1008–1010.
20. Sansović I, Barišić I, Dumić K, Improved detection of deletions and duplications in the DMD gene using the multiplex ligation-dependent probe amplification (MLPA) method. Biochem Genet 51 (2013), 189–201.
21. Hegde, MR, Chin, EL, Mulle, JG, Okou, DT, Warren, ST, Zwick, ME, Microarray-based mutation detection in the dystrophin gene. Hum Mutat 29 (2008), 1091–1099.
22. Ankala, A, da Silva, C, Gualandi, F, et al. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. Ann Neurol 77 (2015), 206–214.
23. Wang, Y, Yang, Y, Liu, J, et al. Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy. Mol Genet Genomics 289 (2014), 1013–1021.
24. Wei, X, Dai, Y, Yu, P, et al. Targeted next-generation sequencing as a comprehensive test for patients with and female carriers of DMD/BMD: a multi-population diagnostic study. Eur J Hum Genet 22 (2014), 110–118.
25. Okubo, M, Minami, N, Goto, K, et al. Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation sequencing: validation analysis of DMD mutations. J Hum Genet 61 (2016), 483–489.
26. American Medical Association. Opinion 2.138—genetic testing of children. http://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics/opinion2138.page, 1996 (accessed March 28, 2016).
27. Dubowitz, V, Screening for Duchenne muscular dystrophy. Arch Dis Child 51 (1976), 249–251.
28. Ellis, JA, Vroom, E, Muntoni, F, 195th ENMC International Workshop: Newborn screening for Duchenne muscular dystrophy 14-16th December, 2012, Naarden, The Netherlands. Neuromuscul Disord 23 (2013), 682–689.
29. Watson, MS, Mann, MY, Lloyd-Puryear, MA, Rinaldo, P, Howell, RR, Newborn screening: toward a uniform screening panel and system. Genet Med 8:suppl (2006), 1S–11S.
30. Wood, MF, Hughes, SC, Hache, LP, et al. Parental attitudes toward newborn screening for Duchenne/Becker muscular dystrophy and spinal muscular atrophy. Muscle Nerve 49 (2014), 822–828.
31. Chung, J, Smith, AL, Hughes, SC, et al. Twenty-year follow-up of newborn screening for patients with muscular dystrophy. Muscle Nerve 53 (2016), 570–578.
32. Henricson, E, Abresch, R, Han, JJ, et al. The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr, 2013, 5.
33. Mazzone, ES, Pane, M, Sormani, MP, et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One, 8, 2013, e52512.
34. Mayhew, AG, Cano, SJ, Scott, E, et al., the North Star Clinical Network for Neuromuscular Disease. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 55 (2013), 1046–1052.
35. McDonald, CM, Henricson, EK, Abresch, RT, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48 (2013), 343–356.
36. Kinnett, K, Noritz, G, The PJ Nicholoff Steroid Protocol for Duchenne and Becker muscular dystrophy and adrenal suppression. PLoS Curr, 9, 2017 ecurrents.md.d18deef7dac96ed135e0dc8739917b6e.
37. Lebel, DE, Corston, JA, McAdam, LC, Biggar, WD, Alman, BA, Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am 95 (2013), 1057–1061.
38. Merlini, L, Gennari, M, Malaspina, E, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 45 (2012), 796–802.
39. Lamb, MM, West, NA, Ouyang, L, et al. Corticosteroid treatment and growth patterns in ambulatory males with Duchenne muscular dystrophy. J Pediatr, 173, 2016, 207 13.e3.
40. Griggs, RC, Herr, BE, Reha, A, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve 48 (2013), 27–31.
41. Bello, L, Gordish-Dressman, H, Morgenroth, LP, et al., the CINRG Investigators. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology 85 (2015), 1048–1055.
42. Escolar, DM, Hache, LP, Clemens, PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77 (2011), 444–452.
43. Bushby, K, Finkel, R, Wong, B, et al., the PTC124-GD-007-DMD STUDY GROUP. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50 (2014), 477–487.
44. McDonald, CM, Campbell, C, Torricelli, RE, et al., the Clinical Evaluator Training Group and the ACT DMD Study Group. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390 (2017), 1489–1498.
45. Mendell, JR, Goemans, N, Lowes, LP, et al., the Eteplirsen Study Group and Telethon Foundation DMD Italian Network. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79 (2016), 257–271.
46. Guiraud, S, Davies, KE, Pharmacological advances for treatment in Duchenne muscular dystrophy. Curr Opin Pharmacol 34 (2017), 36–48.
47. McAdam, LC, Mayo, AL, Alman, BA, Biggar, WD, The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myol 31 (2012), 16–20.
48. Henricson, EK, Abresch, RT, Cnaan, A, et al., the CINRG Investigators. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 48 (2013), 55–67.
49. Connolly, AM, Florence, JM, Cradock, MM, et al., the MDA DMD Clinical Research Network. Motor and cognitive assessment of infants and young boys with Duchenne muscular dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord 23 (2013), 529–539.
50. De Sanctis, R, Pane, M, Sivo, S, et al. Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy. Neuromuscul Disord 25 (2015), 14–18.
51. Mayhew, A, Mazzone, ES, Eagle, M, et al. Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55 (2013), 1038–1045.
52. Lowes, LP, Alfano, LN, Crawfis, R, et al. Reliability and validity of active-seated: an outcome in dystrophinopathy. Muscle Nerve 52 (2015), 356–362.
53. Lee, HN, Sawnani, H, Horn, PS, Rybalsky, I, Relucio, L, Wong, BL, The performance of the upper limb scores correlate with pulmonary function test measures and Egen Klassifikation scores in Duchenne muscular dystrophy. Neuromuscul Disord 26 (2016), 264–271.
54. Jeannet, PY, Aminian, K, Bloetzer, C, Najafi, B, Paraschiv-Ionescu, A, Continuous monitoring and quantification of multiple parameters of daily physical activity in ambulatory Duchenne muscular dystrophy patients. Eur J Paediatr Neurol 15 (2011), 40–47.
55. Mayhew, A, Cano, S, Scott, E, Eagle, M, Bushby, K, Muntoni, F, Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 53 (2011), 535–542.
56. McDonald, CM, Henricson, EK, Abresch, RT, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48 (2013), 357–368.
57. Bartels, B, Pangalila, RF, Bergen, MP, Cobben, NA, Stam, HJ, Roebroeck, ME, Upper limb function in adults with Duchenne muscular dystrophy. J Rehabil Med 43 (2011), 770–775.
58. Pane, M, Mazzone, ES, Fanelli, L, et al. Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord 24 (2014), 201–206.
59. Pangalila, RF, van den Bos, GA, Bartels, B, Bergen, M, Stam, HJ, Roebroeck, ME, Prevalence of fatigue, pain, and affective disorders in adults with Duchenne muscular dystrophy and their associations with quality of life. Arch Phys Med Rehabil 96 (2015), 1242–1247.
60. Sienko Thomas, S, Buckon, CE, Nicorici, A, Bagley, A, McDonald, CM, Sussman, MD, Classification of the gait patterns of boys with Duchenne muscular dystrophy and their relationship to function. J Child Neurol 25 (2010), 1103–1109.
61. Buckon, C, Sienko, S, Bagley, A, et al. Can quantitative muscle strength and functional motor ability differentiate the influence of age and corticosteroids in ambulatory boys with Duchenne muscular dystrophy?. PLoS Curr, 2016 published online July 8. DOI:10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0.
62. Larkindale, J, Abresch, R, Aviles, E, et al. Duchenne Regulatory Science Consortium meeting on disease progression modeling for Duchenne muscular dystrophy. PLoS Curr, 2017, 9.
63. Goemans, N, van den Hauwe, M, Wilson, R, van Impe, A, Klingels, K, Buyse, G, Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscul Disord 23 (2013), 618–623.
64. Pane, M, Mazzone, ES, Sivo, S, et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One, 9, 2014, e108205.
65. Pane, M, Mazzone, ES, Sormani, MP, et al. 6 minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS One, 9, 2014, e83400.
66. Bello, L, Kesari, A, Gordish-Dressman, H, et al. Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study. Ann Neurol 77 (2015), 684–696.
67. Goemans, N, Vanden Hauwe, M, Signorovitch, J, Swallow, E, Song, J, the Collaborative Trajectory Analysis Project (cTAP). Individualized prediction of changes in 6-minute walk distance for patients with Duchenne muscular dystrophy. PLoS One, 11, 2016, e0164684.
68. Ricotti, V, Ridout, DA, Pane, M, et al., the UK NorthStar Clinical Network. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry 87 (2016), 149–155.
69. Landfeldt, E, Lindgren, P, Bell, CF, et al. Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study. Dev Med Child Neurol 58 (2016), 508–515.
70. Reid, DT, Renwick, RM, Preliminary validation of a new instrument to measure life satisfaction in adolescents with neuromuscular disorders. Int J Rehabil Res 17 (1994), 184–188.
71. Reid, DT, Renwick, RM, Relating familial stress to the psychosocial adjustment of adolescents with Duchenne muscular dystrophy. Int J Rehabil Res 24 (2001), 83–93.
72. Narayanaswami, P, Dubinsky, R, Wang, D, et al. Quality improvement in neurology: muscular dystrophy quality measures. Neurology 85 (2015), 905–909.
73. Connolly, AM, Florence, JM, Cradock, MM, et al. One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development. Pediatr Neurol 50 (2014), 557–563.
74. Mercuri, E, Coratti, G, Messina, S, et al. Revised North Star Ambulatory Assessment for young boys with Duchenne muscular dystrophy. PLoS One, 11, 2016, e0160195.
75. Heberer, K, Fowler, E, Staudt, L, et al. Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy. Gait Posture 48 (2016), 159–164.
76. Piper, MC, Darrah, J, Motor assessment of the developing infant. 1994, Saunders.
77. Pane, M, Lombardo, ME, Alfieri, P, et al. Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. J Pediatr, 161, 2012, 705 09.e1.
78. Poysky, J, the Behavior in DMD Study Group. Behavior patterns in Duchenne muscular dystrophy: report on the Parent Project Muscular Dystrophy behavior workshop 8–9 of December 2006, Philadelphia, USA. Neuromuscul Disord 17 (2007), 986–994.
79. Connolly, AM, Florence, JM, Zaidman, CM, et al., the MDA-DMD Clinical Research Network. Clinical trial readiness in non-ambulatory boys and men with Duchenne muscular dystrophy: MDA-DMD network follow-up. Muscle Nerve 54 (2016), 681–689.
80. Connolly, AM, Malkus, EC, Mendell, JR, et al., the MDA DMD Clinical Research Network. Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy. Muscle Nerve 51 (2015), 522–532.
81. Han, JJ, de Bie, E, Nicorici, A, et al. Reachable workspace and performance of upper limb (PUL) in Duchenne muscular dystrophy. Muscle Nerve 53 (2016), 545–554.
82. Glanzman, AM, Flickinger, JM, Dholakia, KH, Bönnemann, CG, Finkel, RS, Serial casting for the management of ankle contracture in Duchenne muscular dystrophy. Pediatr Phys Ther 23 (2011), 275–279.
83. Stuberg, WA, Muscular dystrophy and spinal muscular atrophy. Campbell, SK, Palisano, RJ, Orlin, MN, (eds.) Physical therapy for children, 2012, Elsevier Saunders, St Louis, MO, 353–384.
84. Pardo, AC, Do, T, Ryder, T, Meyer, A, Miles, L, Wong, BL, Combination of steroids and ischial weight-bearing knee ankle foot orthoses in Duchenne's muscular dystrophy prolongs ambulation past 20 years of age—a case report. Neuromuscul Disord 21 (2011), 800–802.
85. Garralda, ME, Muntoni, F, Cunniff, A, Caneja, AD, Knee-ankle-foot orthosis in children with Duchenne muscular dystrophy: user views and adjustment. Eur J Paediatr Neurol 10 (2006), 186–191.
86. Yilmaz, A, Sechtem, U, Cardiac involvement in muscular dystrophy: advances in diagnosis and therapy. Heart 98 (2012), 420–429.
87. Bartels, B, Takken, T, Blank, AC, van Moorsel, H, van der Pol, WL, de Groot, JF, Cardiopulmonary exercise testing in children and adolescents with dystrophinopathies: a pilot study. Pediatr Phys Ther 27 (2015), 227–234.
88. Case, LE, Hartzell, AS, Commentary on “Cardiopulmonary exercise testing in children and adolescents with dystrophinopathies: a pilot study”. Pediatr Phys Ther, 27, 2015, 235.
89. Tidball, JG, Wehling-Henricks, M, Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy. J Physiol 592 (2014), 4627–4638.
90. Abresch, RT, Carter, GT, Han, JJ, McDonald, CM, Exercise in neuromuscular diseases. Phys Med Rehabil Clin N Am 23 (2012), 653–673.
91. Alemdaroğlu, I, Karaduman, A, Yilmaz, OT, Topaloğlu, H, Different types of upper extremity exercise training in Duchenne muscular dystrophy: effects on functional performance, strength, endurance, and ambulation. Muscle Nerve 51 (2015), 697–705.
92. Jansen, M, van Alfen, N, Geurts, AC, de Groot, IJ, Assisted bicycle training delays functional deterioration in boys with Duchenne muscular dystrophy: the randomized controlled trial “no use is disuse”. Neurorehabil Neural Repair 27 (2013), 816–827.
93. Segal, LS, Odgers, R, Carpentieri, D, Shrader, MW, Back pain in Duchenne muscular dystrophy: steroids are not always the culprit. J Pediatr Orthop B 25 (2016), 81–85.
94. Bianchi, ML, Biggar, D, Bushby, K, Rogol, AD, Rutter, MM, Tseng, B, Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord 21 (2011), 298–303.
95. Leung, DG, Germain-Lee, EL, Denger, BE, Wagner, KR, Report on the Second Endocrine Aspects Of Duchenne Muscular Dystrophy Conference December 1–2, 2010, Baltimore, Maryland, USA. Neuromuscul Disord 21 (2011), 594–601.
96. Wood, CL, Straub, V, Guglieri, M, Bushby, K, Cheetham, T, Short stature and pubertal delay in Duchenne muscular dystrophy. Arch Dis Child 101 (2016), 101–106.
97. West, NA, Yang, ML, Weitzenkamp, DA, et al. Patterns of growth in ambulatory males with Duchenne muscular dystrophy. J Pediatr, 163, 2013, 1759 63.e1.
98. Lohman, TG, Roche, AF, Martorell, R, Anthropometric standardization reference manual. 1988, Human Kinetic Books, Champaign, IL.
99. Rutter, MM, Collins, J, Rose, SR, et al. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord 22 (2012), 1046–1056.
100. Zatz, M, Rapaport, D, Vainzof, M, et al. Relation between height and clinical course in Duchenne muscular dystrophy. Am J Med Genet 29 (1988), 405–410.
101. Bodor, M, McDonald, CM, Why short stature is beneficial in Duchenne muscular dystrophy. Muscle Nerve 48 (2013), 336–342.
102. Bhasin, S, Cunningham, GR, Hayes, FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95 (2010), 2536–2559.
103. Wood, CL, Cheetham, TD, Guglieri, M, et al. Testosterone treatment of pubertal delay in Duchenne muscular dystrophy. Neuropediatrics 46 (2015), 371–376.
104. Broersen, LH, Pereira, AM, Jørgensen, JO, Dekkers, OM, Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 100 (2015), 2171–2180.
105. Grossman, AB, Clinical Review: the diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 95 (2010), 4855–4863.
106. van Bruggen, HW, Van Den Engel-Hoek, L, Steenks, MH, et al. Reduced mandibular range of motion in Duchenne muscular dystrophy: predictive factors. J Oral Rehabil 42 (2015), 430–438.
107. Shimizu-Fujiwara, M, Komaki, H, Nakagawa, E, et al. Decreased resting energy expenditure in patients with Duchenne muscular dystrophy. Brain Dev 34 (2012), 206–212.
108. US Department of Health and Human Services and US Department of Agriculture. Dietary guidelines for Americans 2015–2020. 8th edn. https://health.gov/dietaryguidelines/2015/guidelines/#navigation, 2015 (accessed Dec 20, 2017).
109. Motoki, T, Shimizu-Motohashi, Y, Komaki, H, et al. Treatable renal failure found in non-ambulatory Duchenne muscular dystrophy patients. Neuromuscul Disord 25 (2015), 754–757.
110. Institute of Medicine. Dietary reference intakes—the essential guide to nutrient requirements. 2006, The National Academies Press, Washington, DC.
111. Elliott, SA, Davidson, ZE, Davies, PS, Truby, H, Predicting resting energy expenditure in boys with Duchenne muscular dystrophy. Eur J Paediatr Neurol 16 (2012), 631–635.
112. Holliday, MA, Segar, WE, The maintenance need for water in parenteral fluid therapy. Pediatrics 19 (1957), 823–832.
113. Institute of Medicine of the National Academies. Otten, JJ, Hellwig, JP, Meyers, LD, (eds.) Dietary reference intakes: the essential guide to nutrient requirements, 2006, National Academies Press, Washington DC.
114. Institute of Medicine. Ross, AC, Taylor, CL, Yaktine, AL, Valle, HBD, (eds.) Dietary reference intakes for calcium and vitamin D, 2011, The National Academies Press, Washington, DC.
115. Martigne, L, Salleron, J, Mayer, M, et al. Natural evolution of weight status in Duchenne muscular dystrophy: a retrospective audit. Br J Nutr 105 (2011), 1486–1491.
116. Davis, J, Samuels, E, Mullins, L, Nutrition Considerations in Duchenne muscular dystrophy. Nutr Clin Pract 30 (2015), 511–521.
117. American Academy of Pediatrics Committee on Nutrition. [Pediatric Obesity]. Kleinman, RE, Greer, FR, (eds.) Pediatric nutrition, 7th edn., 2014, American Academy of Pediatrics, Elk Grove Village, IL, 827.
118. Toussaint, M, Davidson, Z, Bouvoie, V, Evenepoel, N, Haan, J, Soudon, P, Dysphagia in Duchenne muscular dystrophy: practical recommendations to guide management. Disabil Rehabil 38 (2016), 2052–2062.
119. Archer, SK, Garrod, R, Hart, N, Miller, S, Dysphagia in Duchenne muscular dystrophy assessed by validated questionnaire. Int J Lang Commun Disord 48 (2013), 240–246.
120. Hanayama, K, Liu, M, Higuchi, Y, et al. Dysphagia in patients with Duchenne muscular dystrophy evaluated with a questionnaire and videofluorography. Disabil Rehabil 30 (2008), 517–522.
121. Martigne, L, Seguy, D, Pellegrini, N, et al. Efficacy and tolerance of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr 29 (2010), 60–64.
122. Kraus, D, Wong, BL, Horn, PS, Kaul, A, Constipation in Duchenne muscular dystrophy: prevalence, diagnosis, and treatment. J Pediatr 171 (2016), 183–188.
123. Borrelli, O, Salvia, G, Mancini, V, et al. Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. Am J Gastroenterol 100 (2005), 695–702.
124. Lazarus, B, Chen, Y, Wilson, FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176 (2016), 238–246.
125. Lambert, AA, Lam, JO, Paik, JJ, Ugarte-Gil, C, Drummond, MB, Crowell, TA, Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One, 10, 2015, e0128004.
126. Parks, M, Court, S, Cleary, S, et al. Non-invasive prenatal diagnosis of Duchenne and Becker muscular dystrophies by relative haplotype dosage. Prenat Diagn 36 (2016), 312–320.
127. Fowler, EG, Staudt, LA, Heberer, KR, et al. Longitudinal community walking activity in Duchenne muscular dystrophy. Muscle Nerve, 2017 published online July 10. DOI:10.1002/mus.25743.
128. de Souza, MA, Figueiredo, MM, de Baptista, CR, Aldaves, RD, Mattiello-Sverzut, AC, Beneficial effects of ankle-foot orthosis daytime use on the gait of Duchenne muscular dystrophy patients. Clin Biomech (Bristol, Avon) 35 (2016), 102–110.
129. Angelini, C, Tasca, E, Drugs in development and dietary approach for Duchenne muscular dystrophy. Orphan Drugs Res Rev 5 (2015), 51–60.